Period, end of story. The drug will be approved. At the end of the day, that's ALL that matters. It's very compelling, statistically significant, and a billion dollar drug.
For electric vehicles...a constant source of re-supply, while on the road. Forklift deals are real and justify the technology. Plenty of companies source items from other firms and repackage them into good products. BASF doesn't make the things you use, they make the things you use better...for example.
Andrew Left didn't say anything material. He's a joke. Took advantage of the Quiet Period. Typical short seller.
Adding to this dip, hand over fist.
ISO certification is all well and good, but UQM has not been able to generate much revenue growth since losing the Fisker contract due to that company's bankruptcy. Is this certification really going to suddenly drive new contract wins? If there was a lot of demand for UQM's technology, don't you think management would have either licensed the technology or partnered with an existing ISO certified manufacturer?
I see Feuerstein has been AWFULLY quiet on LJPC run-up. Expect an article bashing the stock...that's how he rolls.
My conclusion is that the biotech space has A LOT of extremely bright leaders / well funded companies. Why in the world would nobody else in the antibiotic space make a bid for Poly's assets if they were so good? Yet, tiny CTIX is able to "steal" the assets for a few million bucks. Hello??? Since the purchase, Leo can't stop pumping up how amazing these assets are...even today, a press release on treating 14 patients. WHO gives a damn about treating 7% of the patients you said you were going to treat? Talk about a bunch of CEO pumping crap...what was the point of that press release? Have a press release telling shareholders something MATERIAL, not telling us something you should be doing.
CTIX valuation is tiny because its leadership is highly questionable. That's it, period. And, Leo can continue to site relative comps in his press releases on the valuation of other biotechs, but until he brings a Chief Operating Officer on board who has a serious and real track record, the Street is going to doubt everything he releases.
Given all of the praise sited by Leo of CTIX's three programs over the past year, the valuation of CTIX should be 2-3x higher. It's not, and that goes to credibility, track record of success. Period. End of story.
I take all CTIX press releases with a grain of salt until Leo / Menon can successfully hire a COO with a great track record. Let's see someone strong join the management team and thus endorse the pipeline.
He crushes LJPC every chance he gets. Anyone have an analysis of what Feuerstein has said vs. the actual facts? Is he just plain wrong again or will he be proven correct?
Please post any thoughts....thanks
Sounds like you're short and saying, "holy smokes, Mika actually made a good hire with a guy who has real credibility...for the first time EVER!"
Adam F is RELENTLESS. Management needs to show the market why they are right and Feuerstein is wrong, or he will continue to hammer this stock, like he does every biotech stock.
Anyone care to refute him? If so, please post why he's wrong.
There always seems to be some #$%$ coming out of an earnings report. Now, they need different distribution. Revenue growth is anemic.
U.S. products may get approved in H2, 2014 and 2015...but, shouldn't we just expect delays there?
Trimming position until after products get approved. Would rather buy back in at a higher price knowing the products got approved, rather than just wait 6 months+ for that pop. Also, starting to question the huge growth opportunity here given the year-over-year declines in revenue in existing approved markets.
JPMorgan downgraded $15 to $8
Jefferies downgraded $5 to $2
Bank of America downgraded $11 to $6
Credit Suisse downgraded from $10 to $7
Wonder what First Manhattan is thinking right now. Biotechs who can't get partnerships closed, have to go it alone and build their own salesforce use A LOT of cash. Qsymia is still the most effective drug in the obesity market, and will remain so. But, doctors are wary about prescribing obesity medications despite the overall strong benefit. So, script numbers, while improving, are not robust enough, and Qsymia pricing also seems confusing and like trial and error. Stendra started to contribute to revenue.
Scripts are taking a lot longer to materialize than ever expected. Given the cash burn on the salesforce, and debt on the books, scripts / cash flow MUST improve or VVUS will likely face the need to raise funds. With the stock diving, that means higher dilution down the road.
Pressure is on management and the salesforce to figure out how to increase scripts, repeat consumers and track all the information better. Overall, a very disappointing situation given how effective both Qsymia and Stendra have proved to be.
What's funny is how so much is riding on meeting the primary endpoint, when one really has to understand medicine today and where clinical trials are going. The goal of any drug is to give the right drug to the right patient, and the increasing focus on clinical protocol today, as the FDA supports, is more targeted patient populations. Now, ONTX's management has a VERY CLEAR patient population for Rigosertib...the ad-hoc, post analysis sub-population. Those are the patients which showed a statistically significant doubling of life expectancy, which is highly meaningful. This sub-population was a large portion of the trial, which is meaningful too. Going forward, I am highly confident that management will work with the FDA to develop a Phase 3 trial to target this sub-population in a multi-center, placebo control trial. And, the results, should be powerful. Expect a trial to start in early 2015, as the remainder of the year is spent analyzing this data, meeting with the FDA to set up the Phase 3 protocol and then enrolling patients.
Ultimately,Rigosertib will double the lives of those patients who should be receiving the drug in the first place...and that is everyone's goal.
Will add more on weakness.
That's 100% wrong, and phen + B is a high-risk cardio play for any physician prescribing it without 2-year studies. Nice try.
Took a pounding on the earnings pop and now are trying to bring this stock down with an article. This is what short sellers do when they missed the boat...they come up with a bunch of #$%$ to get the stock down. Fact is that earnings were excellent and CRAY is running on all cylinders.
Nice try Arora.
Add to positions on pullbacks on the way towards $50+
He will press and press and press negative comments on PRAN until the drug is approved, just like he did for VNDA and VVUS before those drugs were approved.
Expect many many more negative articles and a constant stream of negative Twitter tweats...
But, always remember, he is a political science major.
Both have been outed as having shady backgrounds which warrants a defense. Leo is quick to tout CTIX's drugs in development. Why has he not been quick to defend the backgrounds and past dealings / investments and career work of himself and Dr. Menon?
Where is the clarification? If someone was smearing my name and background, you can bet your #$%$ that I would be defending myself.
NNVC's Management FAILS to refute each point brought up in the article. If it was my company, and a guy wrote this type of article smearing my company, I would GRILL the person, point by point, as to why the article is egregiously inaccurate. Certainly a missed opportunity that makes me question management's credibility. If you don't take the time and hammer this writer, it makes your position weaker.
Call me 100% unimpressed. I'm long NNVC stock and want to buy more on this dip, but until Management either refutes the article point by point or files a lawsuit next week, it's hard to trust this situation as credibility is vital.
Don't expect a redaction by Seeking Alpha. So, let's see if NNVC follows through with a lawsuit.